ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 27 of 1150 for:    cataract

Cataract Refractive Suite Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02974140
Recruitment Status : Terminated (Management Decision)
First Posted : November 28, 2016
Last Update Posted : July 28, 2017
Sponsor:
Information provided by (Responsible Party):
Alcon Research ( Alcon, a Novartis Company )

Brief Summary:
The purpose of this study is to compare the refractive predictability (prediction error) between the Cataract Refractive Suite (CRS) and standard manual technique at one month post-operative

Condition or disease Intervention/treatment Phase
Cataracts Device: Cataract Refractive Suite (CRS) Procedure: Standard manual technique Not Applicable

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 39 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Prospective, Multicenter, Randomized Evaluation of Refractive Predictability in Patients With or Without Corneal Astigmatism (Maximum Allowable up to 1.25D) When Using the Cataract Refractive Suite and Standard Manual Techniques
Actual Study Start Date : March 2, 2017
Actual Primary Completion Date : July 19, 2017
Actual Study Completion Date : July 19, 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Cataract

Arm Intervention/treatment
Experimental: CRS
First surgical eye randomized to Cataract Refractive Suite with second surgical eye (fellow eye) assigned to standard manual technique. Second eye surgery conducted within 7-14 days of the first eye surgery.
Device: Cataract Refractive Suite (CRS)
Configuration consisting of Verion™ Image Guided System, LenSx® Laser and ORA™ System with VerifEye+™ (with or without VerifEye Lynk), combined for use in surgical pre-op planning and during cataract surgery

Procedure: Standard manual technique
Standard biometry for intra-ocular lens (IOL) calculation and cataract removal using phacoemulsification technique

Active Comparator: Manual
First surgical eye randomized to standard manual technique with second surgical eye (fellow eye) assigned to Cataract Refractive Suite. Second eye surgery conducted within 7-14 days of the first eye surgery.
Device: Cataract Refractive Suite (CRS)
Configuration consisting of Verion™ Image Guided System, LenSx® Laser and ORA™ System with VerifEye+™ (with or without VerifEye Lynk), combined for use in surgical pre-op planning and during cataract surgery

Procedure: Standard manual technique
Standard biometry for intra-ocular lens (IOL) calculation and cataract removal using phacoemulsification technique




Primary Outcome Measures :
  1. Percentage of eyes in which the Manifest Refraction Spherical Equivalent (MRSE) at one month is ≤ 0.50 Diopter (D) relative to predicted MRSE [ Time Frame: Day 20-40 from second implantation ]
    Manifest refraction spherical equivalent (MRSE) is calculated as follows: sphere + 1/2 cylinder. The sphere and cylinder values are from the manifest refraction assessment. Manifest refraction will be assessed at 4 meters under photopic lighting conditions using a phoropter.


Secondary Outcome Measures :
  1. Cumulative dissipated energy (CDE) [ Time Frame: Day 0 (operative day), each eye ]
    Cumulative Dissipated Energy (CDE) represents the energy dissipated of the ultrasound tip and infusion sleeve at the incision point during the removal of cataractous lens. CDE will be reported on the Vision System interface and measured in percent-seconds. A lower CDE indicates that less energy was present at the incision site.

  2. Estimated aspiration fluid used [ Time Frame: Day 0 (operative day), each eye ]
    Aspiration fluid is the amount of fluid used during the removal of the cataractous lens. Aspiration fluid will be measured in milliliters (ml).

  3. Phaco aspiration time [ Time Frame: Day 0 (operative day), each eye ]
    The average time the surgeon takes to complete the phacoemulsification will be assessed.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   22 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosed with bilateral cataracts;
  • Planned cataract surgery and implantation of ReSTOR +2.5 D multifocal intraocular lens (IOL) in both eyes;
  • Clear intraocular media, other than cataract, in study eye(s);
  • Willing and able to complete all required postoperative visits;
  • Able to comprehend and sign a statement of informed consent;
  • Other protocol-specified inclusion criteria may apply.

Exclusion Criteria:

  • Significant irregular corneal astigmatism;
  • History of or current severe dry eyes, retinal/uveal pathology or concurrent ocular disease;
  • Previous intraocular or corneal refractive surgery, corneal transplant, or retinal detachment;
  • Any inflammation or edema (swelling) of the cornea;
  • Pregnant;
  • Other protocol-specified exclusion criteria may apply.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02974140


Locations
United States, Florida
Alcon Investigative Site
Panama City, Florida, United States, 32405
United States, Minnesota
Alcon Investigative Site
Stillwater, Minnesota, United States, 55082
United States, Pennsylvania
Alcon Investigative Site
Bala-Cynwyd, Pennsylvania, United States, 19004
United States, Texas
Alcon Investigative Site
Hurst, Texas, United States, 76054
Sponsors and Collaborators
Alcon, a Novartis Company
Investigators
Study Director: Sr. Clinical Manager, GCRA Alcon, A Novartis Division

Responsible Party: Alcon, a Novartis Company
ClinicalTrials.gov Identifier: NCT02974140     History of Changes
Other Study ID Numbers: CTK246-P001
First Posted: November 28, 2016    Key Record Dates
Last Update Posted: July 28, 2017
Last Verified: July 2017

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: No

Additional relevant MeSH terms:
Cataract
Lens Diseases
Eye Diseases